“Laboratory Parameters in Adolescent Patients Aged 12–17 With Moderate-to-Severe Atopic Dermatitis Treated With Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 1 (January 16, 2024): s323. Accessed April 6, 2025. https://skin.dermsquared.com/skin/article/view/2407.